ClearLight Diagnostics to Present Data on the 3D Imaging of Biomarkers in Core Needle Biopsies of Breast Cancer Patients

Posted: December 4, 2017 source: PRNewswire

SUNNYVALE, CA December 4, 2017 (PR NEWSWIRE)

ClearLight Diagnostics, LLC, a developer of an automated next generation tissue processing and 3D imaging platform, announced today that it will present data at the 2017 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

Poster title: Three-dimensional (3D) Imaging of Biomarkers in Human Core Needle Biopsies of Normal and Cancerous Breast Tissue
Authors: Yi Chen, Qi Shen, Laurie J. Goodman, Yesim Gokmen-Polar, Sunil Badve

The tumor microenvironment is spatially and compositionally very heterogeneous, which introduces great challenges to characterize when limited to analyzing samples using standard 2D thin section FFPE methods. Capturing high resolution 3D quantitative biomarker data, while simultaneously preserving morphology of the tumor microenvironment, could lead to a better understanding of key spatial relationships and may lead to better prognostic and predictive clinical outcomes. In this study, we utilized a novel technique, CLARITY, to transform core needle biopsies from patients with breast cancer, into optically transparent tissues, followed by multiplexed immunostaining and 3D imaging of molecular markers. This data was compared to the conventional methods of immunohistochemistry and immunofluorescence staining on FFPE thin sections.  This is the first study demonstrating that other than fresh or frozen tissues, pre-fixed clinical tissue from patients with breast cancer, can be successfully processed by the CLARITY method and 3D imaged, indicating the potential power of this technique for core needle biopsy tissue processing and the identification of biomarkers based on tumor cell heterogeneity.

Abstract #351
Session Date, Time and Location: Friday, December 8, 2017, 5:00PM-7:00 PM in the Convention Center Hall 1
Session Title: Tumor cell and molecular biology: Microenvironments-stromal epithelial interaction
Program Number: P5-03-02

About ClearLight Diagnostics

Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing an integrated instrumentation platform with the associated optimized biomarker panels based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules.

Visit us at www.clearlightdx.com.

Contact:
Sarah McCurdy, CEO
contact@clearlightdx.com
(510) 470-5042

Posted in Uncategorized.